Aroa Biosurgery (ASX:ARX) printed NZ$12.6m EBITDA in FY26 then guided FY27 lower as it reinvests NZ$9m into Myriad and Symphony.
26
Skip to content
Skip to sidebar
Skip to footer
Stocks in Spotlight
View all →-
AI Stocks · Semiconductor stocks SanDisk (NASDAQ:SNDK) The Sell Case Behind a 3,300% AI Memory Rally May 21, 2026 -
Financials · Growth Stocks Powerhouse (ASX:PVL) Why the Re-Rate May Only Be Getting Started May 20, 2026 -
